Supported by an independent educational grant from Lilly

Program Description

The latest evidence and recommendations for detection of targetable genomic alterations in non-small cell lung cancer (NSCLC) are evolving. Join our distinguished faculty experts for an interactive educational symposium as they address best practices for optimizing the identification of molecular alterations in NSCLC, and how to apply the latest clinical trial data and recommendations for personalizing therapy.

Supported by an independent educational grant from Lilly.
This program was approved by the IASLC 2023 World Conference on Lung Cancer Program Committee as an independent CME activity held in conjunction with the IASLC 2023 World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC accredited program.

Speakers

Fernando Lopez-Rios , MD, PhD
Doce de Octubre University Hospital
Department of Pathology
Pathologist
Madrid, Spain

Justin F. Gainor, MD
Massachusetts General Hospital | Harvard Medical School
Center for Thoracic Cancers
Assistant Professor of Medicine
Boston, MA

James Chih-Hsin Yang, MD, PhD
National Taiwan University Hospital
Department of Oncology
Director
Taipei, Taiwan